Mankind Pharma net profit drops 16% to Rs 385 crore in Q3FY25
Mankind Pharma's Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 17%, exports more than doubled, and consumer health grew 30%.
By Viswanath Pilla, ET Bureau |
Reuters
Mankind Pharma net profit dropped 16% YoY to Rs 385 crore in Q3FY25 led by higher expenses. The company reported revenue from operations at Rs. 3,230 Cr, up by 24% YoY.
The adjusted EBITDA rose 46% YoY to Rs 895 crore. Adjusted EBITDA margin of 26.9% up by 210 bps YoY.
Domestic revenue at Rs 2773 crore, up 17%, exports more than doubled to Rs 457 crore. The market share of Mankind has increased in the domestic formulation market from 4.4% in March 2024 to 4.8% as of December 2024 on account of BSV acquisition.
The consumer health segment grew 30% YoY in Q3FY25 supported by steady growth across all key brands like Manforce Condom, Gas-o-fast and HealthOk which grew 13%, 28% and 26% YoY respectively.
The adjusted EBITDA rose 46% YoY to Rs 895 crore. Adjusted EBITDA margin of 26.9% up by 210 bps YoY.
Domestic revenue at Rs 2773 crore, up 17%, exports more than doubled to Rs 457 crore. The market share of Mankind has increased in the domestic formulation market from 4.4% in March 2024 to 4.8% as of December 2024 on account of BSV acquisition.
The consumer health segment grew 30% YoY in Q3FY25 supported by steady growth across all key brands like Manforce Condom, Gas-o-fast and HealthOk which grew 13%, 28% and 26% YoY respectively.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
